Concert Pharmaceuticals (NASDAQ: CNCE) and Matinas BioPharma Holdings (NASDAQ:MTNB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation and Earnings

This table compares Concert Pharmaceuticals and Matinas BioPharma Holdings’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Concert Pharmaceuticals $82,000.00 3,884.46 -$49.11 million ($2.23) -6.30
Matinas BioPharma Holdings $59,875.00 1,950.80 -$12.81 million N/A N/A

Matinas BioPharma Holdings has higher revenue, but lower earnings than Concert Pharmaceuticals.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Concert Pharmaceuticals and Matinas BioPharma Holdings, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concert Pharmaceuticals 0 0 4 0 3.00
Matinas BioPharma Holdings 0 0 3 0 3.00

Concert Pharmaceuticals currently has a consensus price target of $26.75, indicating a potential upside of 90.53%. Matinas BioPharma Holdings has a consensus price target of $7.67, indicating a potential upside of 503.67%. Given Matinas BioPharma Holdings’ higher probable upside, analysts clearly believe Matinas BioPharma Holdings is more favorable than Concert Pharmaceuticals.

Profitability

This table compares Concert Pharmaceuticals and Matinas BioPharma Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Concert Pharmaceuticals -60,681.70% -61.98% -48.50%
Matinas BioPharma Holdings -8,834.65% -143.22% -79.91%

Insider and Institutional Ownership

61.6% of Concert Pharmaceuticals shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Concert Pharmaceuticals beats Matinas BioPharma Holdings on 7 of the 10 factors compared between the two stocks.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company’s product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Matinas BioPharma Holdings Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.